



DATE: September 12, 2023

TO: Commonwealth of Kentucky Medicaid Pharmacy Network

FROM: MedImpact Healthcare Systems

Subject: Updated Medication-Assisted Treatment (MAT) Drugs Dispensing Fee & Professional Service Fees

Effective October 1, 2023, Brixadi (buprenorphine subcutaneous prefilled syringe), a new FDA approved buprenorphine product, will be reimbursed as other Medication-Assisted Treatment (MAT) drugs following the same billing instruction as described below.

Effective October 1, 2022, pursuant to State of Emergency administrative regulation 907 KAR 23:02E, the Commonwealth of Kentucky Department for Medicaid Services (DMS) effectuated reimbursement of up to one (1) dispensing fee every seven (7) days for qualifying MAT drugs used in the treatment of a substance use disorder for Managed Care Organization (MCO) members.

Qualifying MAT drugs include transmucosal Buprenorphine-Mono-Products, Buprenorphine-Combined-with-Naloxone Products, or weekly subcutaneous Buprenorphine prefilled syringe. This was implemented as one (1) dispensing fee and up to three (3) additional professional service fees per rolling 28-day period as described below.

- Pharmacy provider will receive one dispensing fee of \$10.64 every 28 days per member per qualifying MAT drug.
- To receive the additional professional service fees for qualifying MAT drugs, the pharmacy provider must submit required codes in the designated NCPDP fields (refer to Table 1 below).
 - By submitting the required codes, pharmacy provider attests that patient counseling and/or education has been provided or offered to the Medicaid member per the “applicable standard of care” and documented in the patient prescription record.
 - The pharmacy provider must query KASPER prior to each dispensation of a qualifying MAT drug (as defined below).
 - Records documenting the patient counseling, education, or offer to counsel and the review of KASPER are subject to audits.
- Each claim will only be paid with either a dispensing fee or a professional service fee. In the case where a dispensing fee is paid, the professional service fee will not be paid.
- Current dispensing fee limits will continue to apply to non-MAT drugs, injectable buprenorphine (except weekly subcutaneous Buprenorphine prefilled syringe), and XR-naltrexone.



Dispensing Fee

- **Applicable Drugs:** Qualifying MAT drugs
- **Fee Amount:** Up to \$10.64 per claim
- **Limitation:** One (1) dispensing fee every rolling 28 days per member per drug

Professional Service Fee

- **Applicable Drugs:** Qualifying MAT drugs
- **Fee Amount:** Up to \$10.64 per claim
- **Limitation:** One (1) professional service fee every rolling 7 days per member per drug
- **Required claim submission fields and values:**

Table 1

NCPDP Field#	NCPDP Field Name	Required Submitted Value
420-DK	Submission Clarification Code	10 – The pharmacy certifies that the transaction is in compliance with the program's policies and rules that are specific to the particular product being billed.
438-E3	Incentive Amount Submitted	Up to \$10.64
440-E5	Professional Service Code (PSC)	PE – Patient education/instruction

Dispensing Fee & Professional Service Fees Examples

Claim	Drug	Fill Date	440-E5 PSC Subm.	438-E3 Incentive Amount Subm.	Disp. Fee Paid	Prof. Svc Fee Paid	Explanation
1	Brixadi 16mg/0.32mL SYR	10/10/2023	N/A	\$0.00	\$10.64	\$0.00	Dispensing fee paid.
2	Brixadi 8mg/0.16mL SYR	10/12/2023	PE	\$10.64	\$10.64	\$0.00	Current claim is for a different strength (8mg/0.16mL vs. 16mg/0.32mL) therefore dispensing fee is paid.
3	Brixadi 8mg/0.16mL SYR	10/14/2023	PE	\$10.64	\$0.00	\$10.64	Dispensing fee already paid on 10/12/2023. Current claim is within 28 days; professional service fee paid instead



4	Brixadi 32mg/0.64mL SYR	10/21/2023	PE	\$10.64	\$10.64	\$0.00	Current claim is for a different strength (32mg/0.16mL vs. 8mg/0.16mL vs. 16mg/0.32mL) therefore dispensing fee is paid
5	Brixadi 32mg/0.64mL SYR	10/28/2023	N/A	\$0.00	\$0.00	\$0.00	Dispensing fee already paid on 10/21/2023. Current claim is within 28 days; required fields not submitted for professional service fee, therefore no fee is paid

Contact Information: If you have any questions, please contact MedImpact's Kentucky Team at:

Program Questions: KYMCOPBM@MedImpact.com

Pharmacy Help Desk: (800) 210-7628 BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01